Asio Capital’s Novartis NVS Stock Holding History

Asio Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-22,157	Closed	-$2.09M	–	94
2020 Q4	$2.09M	Buy	22,157 +1,220	+6%	+$107K	1%	47
2020 Q3	$1.82M	Buy	20,937 +2,195	+12%	+$190K	1%	50
2020 Q2	$1.64M	Sell	18,742 -815	-4%	-$70.4K	1.04%	50
2020 Q1	$1.61M	Buy	19,557 +5,789	+42%	+$516K	1.38%	31
2019 Q4	$1.3M	Buy	+13,768	New	+$1.24M	0.68%	50

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.7B AUM 13.92% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Asio Capital's NVS Position: Q1 2021 in Review

Asio Capital sold out of Novartis (NVS) in Q1 2021, closing a stake of 22,157 shares — an estimated $2.09M sold.

Asio Capital first reported a position in NVS in Q4 2019 and held it in 5 quarters. The position peaked at $2.09M in Q4 2020. 1,136 funds tracked by Wall St. Rank hold NVS as of Q1 2021.

Asio Capital reported no remaining Novartis position as of Q1 2021 after selling out during the quarter.
Asio Capital sold 22,157 Novartis shares in Q1 2021, an estimated $2.09M.
Asio Capital first reported a position in Novartis in Q4 2019 and held it in 5 quarters.
Asio Capital's Novartis position peaked at $2.09M in Q4 2020.
1,136 funds tracked by Wall St. Rank held Novartis as of Q1 2021.

Based on Asio Capital's 13F filing for Q1 2021, filed 5 May 2021.